Bioelectronica nabs financing to advance antibody discovery platform

By The Science Advisory Board staff writers

February 8, 2021 -- Proxima Ventures and Co-win Ventures have invested in Bioelectronica to advance the company's digital biochemistry innovations, including novel assay development and electrofluidics.

Bioelectronica will use the series A financing to expand its team, drive new applications in cell line development, and further antibody discovery for the Hypercell platform. The capital will also be used for scaling the numbers of clients served through product sales of Hypercell, custom assay development, and contract research.

Hypercell is the company's proprietary single-cell sorting system that uses computer vision, data science, and lensless imaging to enable single-cell sorting assays with high throughput. Bioelectronica is using the platform to identify productive cells in antibody discovery and accelerate development with its computer vision single-cell sorting system.

Copyright © 2021

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter